Loading
A phase 1/2 trial of MHB046C in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.
A Study of MHB046C Injection in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06985355 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants planned, started 2025-07-17 and due to reach its primary completion in 2029-05. Interventions recorded: MHB046C.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/